British Journal of Haematology · 2009 · 48 citations · 14 references
MedicineNuclear MedicineOncologyChemotherapyMolecular ImagingOncologic ImagingChemotherapy In Hematologic MalignanciesHigh-dose ChemotherapyLymphoma ImagingPositron Emission TomographyTherapy Response AssessmentTumor ImagingHodgkin Lymphoma ImagingHodgkin Lymphoma TreatmentInterim Positron Emission TomographyOncologic Pet ImagingPositive Predictive ValuePositron Emission Tomography PrognosisRefractory Hodgkin LymphomaRelapsed Hodgkin Lymphoma
This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P < 0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.
14
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
Norbert Schmitz, Beate Pfistner, M. Sextro et al. · The Lancet · 2002 · 1.1K citations
洋行 小林 · Mebio oncology · 2007 · 242 citations